Therapy News and Research

RSS

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Three of the world's top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.

1 Feb 2011

Current prevention efforts delay but do not prevent HCV among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV.

1 Feb 2011

New study finds link between race and treatment delay in women with breast cancer

At a time when access to prompt treatment might affect survival, a large new study finds that African-American and Hispanic women newly diagnosed with breast cancer often face delays in care of more than a month.

1 Feb 2011

MRI T2 can determine iron overload in beta-thalassemic patients

Iron overload is a common and serious problem in thalassemic major patients. As iron accumulation is toxic in the body's tissues, accurate estimation of iron stores is of great importance in these patients to prevent iron overload by an appropriate iron chelating therapy.

1 Feb 2011

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

Florida-based biopharmaceutical company Oragenics, today announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy.

31 Jan 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

National Jewish Health scientists identify signaling pathway for ALI

Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.

31 Jan 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

KCI announces agreement to license Wright Medical Group's GRAFTJACKET for wound care

Kinetic Concepts, announced today an agreement to license Wright Medical Group, GRAFTJACKET brand for use in marketing the LifeCell™ acellular human dermal-based regenerative tissue matrix for wound applications such as diabetic foot ulcers and venous stasis ulcers.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“ASK”). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.

31 Jan 2011

$61 million anti-tobacco campaign launched to prevent lung cancer

The Australian Federal Government is backing a $61 million advertising campaign to stop smoking. This is the nation’s biggest anti-tobacco campaign. The message is graphic and simple: every cigarette brings cancer closer. Health groups have backed the campaign but advertising industry experts say the public has become increasingly immune to scare campaigns.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

After a spinal cord injury a number of factors impede the regeneration of nerve cells. Two of the most important of these factors are the destabilization of the cytoskeleton and the development of scar tissue.

29 Jan 2011

Therapy News and Research

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Current prevention efforts delay but do not prevent HCV among injection drug users

New study finds link between race and treatment delay in women with breast cancer

MRI T2 can determine iron overload in beta-thalassemic patients

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Oragenics to commence second phase 1 clinical trial for SMaRT Replacement Therapy

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

National Jewish Health scientists identify signaling pathway for ALI

Baxter launches OLIMEL emulsion for parenteral nutrition

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

KCI announces agreement to license Wright Medical Group's GRAFTJACKET for wound care

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

$61 million anti-tobacco campaign launched to prevent lung cancer

EU grants 3.3 million to AMP for gene therapy development against AIP

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Taxol reduces cell regeneration obstacles after spinal cord injury: Scientists

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News